Decline in sales due to intensifying competition in clinical laboratory reagents
First written in FY2018-Q1. 12 of 25 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024DroppedAnnual report
「Reagents and consumables increased due to new adoptions, but fell below the previous fiscal year because the number of COVID-19 tests declined at individual facilities and testing methods changed.」
Intensifying competition, which had been cited through FY2023 as a factor behind the decline in clinical laboratory reagent sales, was not explicitly mentioned in the FY2024 explanation of medical segment performance; decreases in infection testing volumes and changes in testing methods were cited instead. - FY2023MaterialisedAnnual report
「Clinical laboratory reagents fell below the previous consolidated fiscal year due in part to the impact of intensifying competition and a decrease in reagents for COVID-19-related testing.」
Intensifying competition and a decrease in infection-related testing reagents materialized as a full-year decline in clinical laboratory reagent sales. - FY2023-Q3MaterialisedAnnual report
「Clinical laboratory reagents fell below the same quarter of the previous year due in part to the impact of intensifying competition and a decrease in reagents for COVID-19-related testing.」
Intensifying competition, together with a decrease in infection-related testing reagents, emerged as a factor behind the decline in clinical laboratory reagent sales, while related equipment also fell below the same quarter of the previous year. - FY2023-Q2MaterialisedAnnual report
「Clinical laboratory reagents fell below the same quarter of the previous year due in part to the impact of intensifying competition and a decrease in reagents for COVID-19-related testing.」
Intensifying competition, together with a decrease in infection-related testing reagents, emerged as a factor behind the decline in clinical laboratory reagent sales. - FY2023-Q1RestatedAnnual report
「Clinical laboratory reagents exceeded the same quarter of the previous year, despite the impact of intensifying competition, due in part to an increase in reagents for COVID-19-related testing.」
The impact of intensifying competition continues to be reported, but sales of clinical laboratory reagents exceeded the same quarter of the previous year due to an increase in infection-related testing reagents. - FY2022RestatedAnnual report
「Clinical laboratory reagents exceeded the previous consolidated fiscal year, despite the impact of intensifying competition, due in part to an increase in reagents for COVID-19-related testing and a growing trend in specimen testing.」
The impact of intensifying competition continues to be reported, but sales of clinical laboratory reagents exceeded the previous year due in part to an increase in infection-related testing reagents. - FY2022-Q3RestatedAnnual report
「Clinical laboratory reagents exceeded the same quarter of the previous year, despite the impact of intensifying competition, due in part to an increase in reagents for COVID-19-related testing.」
The impact of intensifying competition continues to be reported, but sales of clinical laboratory reagents exceeded the same quarter of the previous year due to an increase in infection-related testing reagents. - FY2022-Q2RestatedAnnual report
「Clinical laboratory reagents exceeded the same quarter of the previous year, despite the impact of intensifying competition, due in part to an increase in reagents for COVID-19-related testing.」
The impact of intensifying competition continues to be reported, but sales of clinical laboratory reagents exceeded the same quarter of the previous year due to an increase in infection-related testing reagents. - FY2022-Q1RestatedAnnual report
「Clinical laboratory reagents exceeded the same quarter of the previous year, despite the impact of intensifying competition, due in part to an increase in reagents for COVID-19-related testing.」
The impact of intensifying competition continues to be reported, but sales of clinical laboratory reagents exceeded the same quarter of the previous year due to an increase in infection-related testing reagents. - FY2021RestatedAnnual report
「Clinical laboratory reagents substantially exceeded the previous consolidated fiscal year, despite the impact of intensifying competition, due in part to an increase in reagents for COVID-19-related testing and a growing trend in specimen testing.」
The impact of intensifying competition continues to be reported, but full-year sales substantially exceeded the previous year due to an increase in infection-related testing reagents and a growing trend in specimen testing. - FY2021-Q3RestatedAnnual report
「Clinical laboratory reagents substantially exceeded the same quarter of the previous year, despite the impact of intensifying competition, due in part to an increase in reagents for COVID-19-related testing and a growing trend in specimen testing.」
The impact of intensifying competition continues to be reported, but sales of clinical laboratory reagents substantially exceeded the same quarter of the previous year due to an increase in infection-related testing reagents and a growing trend in specimen testing. - FY2021-Q2RestatedAnnual report
「Clinical laboratory reagents substantially exceeded the same quarter of the previous year, despite the impact of intensifying competition, due in part to an increase in reagents for COVID-19-related testing and a growing trend in specimen testing.」
The impact of intensifying competition continues to be reported, but sales of clinical laboratory reagents substantially exceeded the same quarter of the previous year due to an increase in infection-related testing reagents and a growing trend in specimen testing. - FY2021-Q1RestatedAnnual report
「Sales of clinical laboratory reagents significantly exceeded the same quarter of the previous year due to an increase in COVID-19-related testing reagents and other factors, despite the impact of intensifying competition.」
The impact of intensifying competition, which was not explicitly mentioned in the full-year report, was cited again. However, sales of clinical laboratory reagents significantly exceeded the same quarter of the previous year due to an increase in COVID-19-related testing reagents. - FY2020DroppedAnnual report
「Clinical laboratory reagent sales exceeded the same period of the previous year due to new adoptions and growth in test reagents for COVID-19, despite a decline in the number of specimen tests caused by the COVID-19 pandemic.」
The full-year explanation of clinical laboratory reagents does not explicitly mention the previously cited intensifying competition, instead attributing performance to a decline in the number of specimens tested, new adoptions and an increase in infectious disease testing reagents. - FY2020-Q3RestatedAnnual report
「Sales of clinical laboratory reagents exceeded the same quarter of the previous year due to new projects and other factors, despite the impact of intensifying competition and a decline in the number of specimens.」
Although the impact of intensifying competition and the decline in the number of specimens continues, sales of clinical laboratory reagents exceeded the same quarter of the previous year due to new projects and other factors. - FY2020-Q2RestatedAnnual report
「Sales of clinical laboratory reagents exceeded the same quarter of the previous year due to new projects and other factors, despite the impact of intensifying competition and a decline in the number of specimens.」
Although the impact of intensifying competition and the decline in the number of specimens continues, sales of clinical laboratory reagents exceeded the same quarter of the previous year due to new projects and other factors, limiting the decline. - FY2020-Q1MitigatedAnnual report
「Sales of clinical laboratory reagents exceeded the same quarter of the previous year due to orders for new projects and other factors, despite the impact of intensifying competition.」
Although the impact of intensifying competition continues to be mentioned, sales of clinical laboratory reagents exceeded the same quarter of the previous year due to orders for new projects and other factors, partly offsetting the decline caused by intensifying competition. - FY2019MaterialisedAnnual report
「Sales of clinical laboratory reagents were below the same period of the previous year due to intensifying competition and a decline in the number of specimens tested, despite new adoptions of testing reagents and other factors.」
In addition to intensifying competition, a decline in the number of specimens tested was identified as a factor, and the decline in clinical laboratory reagent sales emerged in the full-year results. - FY2019-Q3MaterialisedAnnual report
「Sales of clinical laboratory reagents were below the same quarter of the previous year, partly due to intensifying competition.」
The disclosure continues to state that sales of clinical laboratory reagents were below the same quarter of the previous year due to intensifying competition, indicating that the risk has emerged in the cumulative third-quarter results. - FY2019-Q2MaterialisedAnnual report
「Sales of clinical laboratory reagents were below the same quarter of the previous year, partly due to intensifying competition.」
The disclosure continues to state that sales of clinical laboratory reagents were below the same quarter of the previous year due to intensifying competition, indicating that the risk has emerged in the cumulative results for the current quarter. - FY2019-Q1MaterialisedAnnual report
「Sales of clinical laboratory reagents were below the same quarter of the previous year, partly due to intensifying competition.」
The full-year report had temporarily omitted references to intensifying competition, but the current quarter's disclosure states that sales of clinical laboratory reagents fell below the same quarter of the previous year due to its impact. - FY2018DroppedAnnual report
「Sales of clinical laboratory reagents were below the same period of the previous year because certain specimen-testing items were adopted on a spot basis in the previous period.」
The references to intensifying competition in the first- and third-quarter disclosures were not included in the full-year explanation of clinical laboratory reagent results, which reverted to the impact of spot adoption in the previous period. - FY2018-Q3MaterialisedAnnual report
「Sales of clinical laboratory reagents were below the same quarter of the previous year, partly due to intensifying competition.」
The impact of intensifying competition also emerged in the cumulative third-quarter results, with sales of clinical laboratory reagents falling below the same quarter of the previous year. - FY2018-Q2RestatedAnnual report
「Sales of clinical laboratory reagents exceeded the same quarter of the previous year, despite the impact of intensifying competition.」
Although the impact of intensifying competition continues to be mentioned, cumulative sales of clinical laboratory reagents for the second quarter exceeded the same quarter of the previous year. - FY2018-Q1First statedAnnual report
「Sales of clinical laboratory reagents were slightly below the same quarter of the previous year, partly due to intensifying competition.」
The company states that intensifying competition actually contributed to the year-on-year decline in sales of clinical laboratory reagents.